OptiBiotix Health plc
(ÒOptiBiotixÓ or the ÒCompanyÓ)
Result of AGM
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.
As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information
For further information, please contact:
| OptiBiotix Health plc | ||
| Neil Davidson, Chairman | Contact via Walbrook below | |
| Stephen O'Hara, Chief Executive |
| |
|
|
| |
| Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | | |
| | | |
| Cenkos Securities plc (Broker) | Tel: 020 7397 8900 | |
| Callum Davidson / Neil McDonald |
| |
| Michael Johnson / Russell Kerr (Sales) |
| |
|
|
| |
| Walbrook PR Ltd | Mob: 07876 741 001 | |
| Anna Dunphy |
| |
|
About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes.
| |
| | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
